Background Evaluation of the clinical efficacy and safety of icotinib in advanced
nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR …

Background This study focused on comparing the safety and therapeutic effects between
icotinib monotherapy and icotinib plus bevacizumab combined therapy in non‐small cell …

Background: This study aimed to evaluate the efficacy, safety and prognostic factors of
icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with …

The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …

To explore a better treatment strategy for patients with advanced non‐small cell lung cancer
harboring sensitive epidermal growth factor receptor mutations, a total of 271 patients were …

Purpose This study was conducted to compare the efficacy of a combination of icotinib and
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …

Background and objective As the first epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo …

背景与目的 靶向治疗已经成为晚期非小细胞肺癌 (non-small cell lung cancer, NSCLC)
治疗中不可或缺的重要手段, 表皮生长因子受体 (epithelial growth factor receptor, EGFR) …

Background: Icotinib is the first generation of epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) independently developed in China, which has been widely used …

Objective: To evaluate the safety and efficacy of icotinib as first-line therapy in Chinese non-
small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) …